The Case against excessive cost sharing

American Journal of Managed Care

Volumn 12, Issue SUPPL. 6, 2006, Pages

  Brixner, Diana I ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIULCER AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

CHRONIC DISEASE; CONFERENCE PAPER; DRUG USE; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HEALTH INSURANCE; PATIENT ATTITUDE; PRIORITY JOURNAL;

ADULT; AGED; BIOLOGICAL PRODUCTS; COST SHARING; COST-BENEFIT ANALYSIS; DEDUCTIBLES AND COINSURANCE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MANAGED CARE PROGRAMS; PATIENT COMPLIANCE; UNITED STATES;

EID: 33645897334     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
2. The RAND Corporation. How cost sharing affects use of drugs by the chronically ill. Available at: http://www.rand.org/publications/RB/RB9109/ RAND_RB 9109.pdf. Accessed January 12, 2006.
3. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344-2350.
4. US Census Bureau. 2004 American community survey. Available at: http://factfinder.census.gov/servlet/STTable?_bm=y&-geo_id= 01000US&-qr_name= ACS_2004_EST_G00_S1901&-ds_name=ACS_2004_EST_G00_. Accessed February 2, 2006.
5. Erkan D, Yaziei Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum. 2002;47:285-290.
6. Gabriel SE, Coyle D, Moreland LW, et al. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics. 2001;19:715-728.
7. Sandborn WJ, Sands BE, Panaccione R, Feagan BG. Optimizing management of Crohn's disease: a case-based discussion of current and future therapies. Available at: http://www.medscape.com/viewprogram/4284. Accessed September 23, 2005.
8. Feagan BG, Enns R, Fedorak RN, et al. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol. 2001; 8:188-198.
9. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96.